Some lung cancer patients may experience durable disease control even after discontinuing immunotherapy

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control, according to findings published in Clinical Cancer Research…